Co-Diagnostics JV CoSara Receives Clearance from Indian FDA for COVID-19 2-Gene Multiplex Test

December 4, 2020

Co-Diagnostics announced November 25 that CoSara Diagnostics Pvt Ltd (“CoSara,” or the “JV”), its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization (“CDSCO”) in India to manufacture and sell its Saragene™ COVID-19 2-gene multiplex RT-PCR test.

Dwight Egan, CEO of Co-Diagnostics, said “tests built on our CoPrimer technology have several advantages over other platforms, including the enhanced multiplex capabilities. We believe that the highly specific nature of the new Saragene test which follows World Health Organization guidance will help CoSara be able to play an even more active role in the battle against this pandemic.”

CoSara Director Mohal Sarabhai remarked “Our honorable Prime Minister Shri Narendra Modi has endorsed the hike in number of available RT-PCR tests to keep the COVID-19 positivity rate under 5%.”

The Saragene test kit approved by the CDSCO uses the Company’s patented CoPrimer™ technology and is based on a test originally designed by Co-Diagnostics that recently received a CE marking for its Logix Smart™ SARS-CoV-2 (genes RdRp/E) multiplex test. Both the CoSara and Co-Diagnostics test target two gene markers of the SARS-CoV-2 genome, RdRp and E-gene, to identify the presence of the virus, and were designed to meet the needs of those markets where government or regulatory bodies recommend a multi-target coronavirus diagnostic. 

“As one of Utah’s growing molecular diagnostic companies, Co-Diagnostics continues to shine, developing innovative, state-of-the-art testing technology,” noted Kelvyn Cullimore, president and CEO of BioUtah.